Project Grant R01CA284362
Award Date
8/15/24
Completion Date
7/31/29
Dollars Obligated
$409K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This $2,186,372 Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports a 5-year research program focused on understanding the processes underlying cancer initiation and progression. The program involves three interdisciplinary research projects at the University of California, Irvine, which will leverage mathematical modeling, genomics, and computational biology to investigate: Stochastic, non-genetic transitions in the development of...
This $368,288 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at the University of California, Davis to understand the molecular mechanisms of homologous recombination and chromosomal maintenance in humans. The key objectives are to investigate the functions of BRCA2, RAD51, and the RAD51 paralogs in DNA repair and genome stability, and how defects in these proteins contribute to cancer predisposition. The research will...
This federal Project Grant award of $341,248.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research at Tulane University to study polyploidy and sex dimorphism in a Drosophila (fruit fly) tumor model. The key objectives are to: (1) determine how polyploid cell divisions contribute to tumor growth and progression, and (2) characterize the sexual dimorphism observed in the tumor model. The research aims to provide a better...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in the amount of $942,442. The grant, awarded on September 1, 2024, will support research to identify the mechanisms driving rapid evolution of cancer genomes, with a focus on understanding catastrophic mutational processes like chromothripsis and chromoplexy. The research, conducted at DFCI's facilities in Boston, MA,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel therapeutic strategy targeting mutant p53, a gene known to drive tumor progression, metastasis, and therapy resistance in more than half of human cancers. The $590,625 award to the University of California, Davis (UC Davis) will fund a 5-year project (3/1/2025 - 2/28/2030) to investigate how the CDK4/6-RBM38-eIF4G axis regulates mutant p53 expression,...
This federal Project Grant award from the National Cancer Institute's (NCI) Cancer Treatment Research program (CFDA 93.395) provides $196,267 to the University of California, Irvine (UC Irvine) to advance novel cancer prevention and therapeutic strategies across NCI's clinical trial networks. The funding will enable the principal investigator (PI) to continue providing strong leadership in their roles on NCI committees, complete an ongoing race/ethnically diverse NCI clinical trial, and expand...
The National Cancer Institute (NCI) awarded a $541,682 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The Trustees of Columbia University in the City of New York for the "Maintenance of Genome Stability in 3D - Cancer Cells" project. The 5-year grant, effective July 3, 2024 through June 30, 2029, will support research to better understand the mechanisms responsible for the assembly of DNA repair domains in cancer cells and evaluate the...
The National Cancer Institute (NCI) awarded a $138,489 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the University of California, Irvine (UC Irvine). The grant, effective from Sep 20, 2025 to Sep 19, 2027, will support research to characterize mechanisms for using arginine methylation to target intracellular proteins for lysosomal degradation, as an alternative to the ubiquitin-proteasome system. This novel approach aims to address limitations of...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $335,470 to Duke University to conduct research focused on understanding how chromosomal instability and the loss of chromosome 17p contribute to cancer cell sensitivity to the inhibition of the NDE1 protein. The research aims to define the relationship between NDE1 dependence, 17p loss, and chromosomal instability, characterize NDE1's role in chromosome segregation, and assess the...
The National Institute of General Medical Sciences (NIGMS) awarded a $2,352,994 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to the Trustees of Indiana University to fund research on cell cycle and checkpoint variations in development and disease. The project, led by the Calvi Lab, will use the Drosophila melanogaster model system to investigate how variations in cell cycle and checkpoints, including a variant called the endocycle, relate to developmental processes and...